Background: Drug–drug interactions (DDIs) are frequent and potentially harmful in pediatric cancer patients due to polypharmacy and complex chemotherapy regimens. However, data on DDIs in hospitalized pediatric oncology patients remain limited, particularly in Middle Eastern settings. Methods: In this prospective study, we analyzed prescriptions for hospitalized pediatric oncology patients in Iran to assess the prevalence, severity, and nature of potential DDIs (PDDIs). Chemotherapy and supportive medications were analyzed using two validated databases (Lexi-Interact™ and Drugs.com™) between November 2019 and June 2020. Results: Of 80 patients (median age 8.9 years), 21.2% had at least one documented PDDI. We identified 197 total PDDIs involving 42 unique drug pairs. The most common DDIs included acetaminophen and granisetron (severity rating: moderate). Methotrexate and vincristine were the most frequent antineoplastic DDI pair. Methotrexate alone accounted for 156 interactions. Conclusions: This is the first prospective study from Iran—and the largest in the region—investigating PDDIs in pediatric oncology. The dual-database screening approach improved PDDI detection. Clinical teams should routinely evaluate medication profiles in pediatric cancer patients to minimize avoidable harms from DDIs.
背景：在儿科癌症患者中，由于多重用药和复杂的化疗方案，药物相互作用（DDIs）频繁发生且具有潜在危害。然而，关于住院儿科肿瘤患者中DDIs的数据仍然有限，尤其是在中东地区。方法：在这项前瞻性研究中，我们分析了伊朗住院儿科肿瘤患者的处方，以评估潜在药物相互作用（PDDIs）的普遍性、严重性和性质。在2019年11月至2020年6月期间，使用两个经过验证的数据库（Lexi-Interact™和Drugs.com™）对化疗和支持性药物进行了分析。结果：在80名患者（中位年龄8.9岁）中，21.2%的患者至少记录到一次PDDI。我们共识别出197个PDDIs，涉及42种独特的药物组合。最常见的DDIs包括对乙酰氨基酚和格拉司琼（严重程度评级：中度）。甲氨蝶呤和长春新碱是最常见的抗肿瘤药物DDI组合。仅甲氨蝶呤就涉及156次相互作用。结论：这是伊朗首个也是该地区规模最大的针对儿科肿瘤患者PDDIs的前瞻性研究。双数据库筛查方法提高了PDDI的检出率。临床团队应常规评估儿科癌症患者的用药情况，以尽量减少DDIs带来的可避免伤害。
肿瘤(癌症)患者之家